Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of KH658 intravitreal injection in neovascular age-related macular degeneration
CTR20242112Phase 2Active
- Sponsor
- Chengdu Hongji Biotech
- Start
- Jul 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of KH658 in exudative macular degeneration, sponsored by Chengdu Hongji Biotech. Started Jul 2024; status: active.
02
Drugs
KH658
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20242112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242112.